Unraveling the etiology of primary malignant melanoma of the esophagus

Recent next generation sequencing (NGS) screens have led to a refined understanding the molecular classification of cancer, uncovering both distinct as well as shared mutations across organ systems. Of special interest are shared mutations, as they allow for cross-cancer use of approved therapies, such as vemurafenib, initially approved for melanomas, on other tumors with BRAF mutations.